Phase 3 Clinical Trials With Primary Completion Dates in June 2020
This is a list of Phase 3 trials with primary completion dates in June 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ABSCF | AB Science S.A. | 2020-06-01 | Phase 3 | NCT01694277 | Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib |
| AKBA | Akebia Therapeutics, Inc. | 2020-06-01 | Phase 3 | NCT02680574 | Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) |
| AKBA | Akebia Therapeutics, Inc. | 2020-06-01 | Phase 3 | NCT02648347 | Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) |
| AKCA | Akcea Therapeutics, Inc. | 2020-06-01 | Phase 3 | NCT02658175 | The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome |
| AMAG | AMAG Pharmaceuticals, Inc. | 2020-06-01 | Phase 3 | NCT03297216 | Improving Pregnancy Outcomes With Progesterone |
| APLS | Apellis Pharmaceuticals, Inc. | 2020-06-01 | Phase 3 | NCT04085601 | A Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH |
| APRE | Aprea Therapeutics, Inc. | 2020-06-01 | Phase 3 | NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) |
| BCDA | BioCardia, Inc. | 2020-06-01 | Phase 3 | NCT02438306 | CardiAMP⢠Heart Failure Trial |
| BYSI | BeyondSpring Inc. | 2020-06-01 | Phase 3 | NCT03102606 | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 |
| CANF | Can-Fite BioPharma Ltd. | 2020-06-01 | Phase 3 | NCT02647762 | CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis |
| CATB | Catabasis Pharmaceuticals, Inc. | 2020-06-01 | Phase 3 | NCT03703882 | Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy |
| CHHL | China Holdings, Inc. | 2020-06-01 | Phase 3 | NCT03660059 | A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) |
| CPHI | China Pharma Holdings, Inc. | 2020-06-01 | Phase 3 | NCT03660059 | A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) |
| ENDP | Endo International plc | 2020-06-01 | Phase 3 | NCT02687451 | Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects |
| HESG | Health Sciences Group, Inc. | 2020-06-01 | Phase 3 | NCT02703389 | Improving Knowledge Translation Upon Emergency Department Discharge |
| HESG | Health Sciences Group, Inc. | 2020-06-01 | Phase 3 | NCT03740048 | A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease |
| HRTX | Heron Therapeutics, Inc. | 2020-06-01 | Phase 3 | NCT03907176 | Herniorrhaphy Study for Opioid Elimination |
| INO | Inovio Pharmaceuticals, Inc. | 2020-06-01 | Phase 3 | NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) |
| IONS | Ionis Pharmaceuticals, Inc. | 2020-06-01 | Phase 3 | NCT02658175 | The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | 2020-06-01 | Phase 3 | NCT03737110 | RHAPSODY Phase 3 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis |
| KPTI | Karyopharm Therapeutics Inc. | 2020-06-01 | Phase 3 | NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma |
| MRDH | Meridian Holdings, Inc. | 2020-06-01 | Phase 3 | NCT01877837 | Stem Cell Transplantation for Sickle Cell Anemia |
| RDUS | Radius Health, Inc. | 2020-06-01 | Phase 3 | NCT03512262 | Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM) |
| SNGX | Soligenix, Inc. | 2020-06-01 | Phase 3 | NCT03237325 | DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer |
| STSA | Satsuma Pharmaceuticals, Inc. | 2020-06-01 | Phase 3 | NCT03901482 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine |